Trial Profile
Pomalyst®Capsules Special Use-results Surveillance (All-case Surveillance)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 30 Jun 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 New trial record